Intelligence for Hematology & Oncology Specialists

Hematologic oncology clinical trials
recruiting in the United States and Brazil

Up-to-date overview of clinical trials in multiple myeloma, acute myeloid leukemia, CLL, DLBCL, follicular lymphoma, mantle cell lymphoma, myelodysplastic syndromes, AL amyloidosis and other hematologic malignancies recruiting patients in the US and Brazil — automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centers.

218

Active trials

2409

US sites

Indications covered

BR trials

Loading map…

218 studies found

N/DNon Hodgkin LymphomaHodgkin DiseaseLeucemia Linfocitica CronicaUS 1 site in the US

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Dana-Farber Cancer Institute

📍 Boston👥 1500 participants📅 Completion: 2033-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DBrain And Central Nervous System TumorsLeucemiaLinfomaUS 1 site in the US

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Barbara Ann Karmanos Cancer Institute

📍 Detroit📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DHairy Cell LeukemiaLeucemia Linfocitica CronicaLinfoma Nao HodgkinUS 1 site in the US

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

National Cancer Institute (NCI)

📍 Bethesda👥 1263 participants

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Mieloide AgudaSindrome Mielodisplasica Alto RiscoUS 1 site in the US

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

📍 Houston👥 160 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DHodgkin LymphomaLinfoma Nao HodgkinMieloma MultiploUS 1 site in the US

Tissue Collection for Studies of Lymph Cancer

National Cancer Institute (NCI)

📍 Bethesda👥 1295 participants

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Non Hodgkin LymphomaLeucemia Linfocitica CronicaLeucemia Linfoblastica AgudaUS 2 sites in the US

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Baylor College of Medicine

📍 Houston👥 64 participants📅 Completion: 2036-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Fanconi Anemia Aplasia GraveSindrome MielodisplasicaLeucemia Mieloide AgudaUS 2 sites in the US

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Children's Hospital Medical Center, Cincinnati

📍 Cincinnati, Seattle👥 70 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaMgus Alto RiscoMieloma SmolderingUS 3 sites in the US

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

Baylor College of Medicine

📍 Houston👥 36 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaUS 10 sites in the US

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Karyopharm Therapeutics Inc

📍 Boston, Chapel Hill, Durham, Gilbert, Hackensack, Los Angeles, Madison, Nashville👥 300 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DTricuspid RegurgitationInsuficiencia Cardiaca Nyha Iii ivUS 1 site in the US

Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients

University of Washington

📍 Seattle👥 40 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide Aguda Nao TratadaLeucemia Mieloide Aguda Recidivada RefratariaUS 12 sites in the US

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Beat AML, LLC

📍 Atlanta, Baltimore, Chapel Hill, Chicago, Cincinnati, Columbus, Dallas, Fairway👥 3000 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DFollicular LymphomaUS 1 site in the US

Clonal Evolution in Follicular Lymphoma

National Cancer Institute (NCI)

📍 Bethesda👥 200 participants📅 Completion: 2029-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Diffuse Large b Cell LymphomaBurkitt LymphomaFollicular LymphomaUS 1 site in the US

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Cancer Institute (NCI)

📍 Bethesda👥 155 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DLeucemia Linfocitica CronicaLinfoma Nao Hodgkin Celulas bLinfoma Linfocitico PequenoUS 1 site in the US

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Medical College of Wisconsin

📍 Milwaukee👥 500 participants📅 Completion: 2035-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Myelodysplastic SyndromeLeucemia Mieloide Aguda 20 30 BlastosLeucemia Mielomonocitica CronicaUS 1 site in the US

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

M.D. Anderson Cancer Center

📍 Houston👥 63 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Mantle Cell LymphomaUS 1 site in the US

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

City of Hope Medical Center

📍 Duarte👥 28 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DGamopatia Monoclonal de Significado IndeterminadoMieloma Multiplo SmolderingMieloma MultiploUS 1 site in the US

The Indiana Myeloma Registry

Indiana University

📍 Indianapolis👥 2500 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Acute Myeloid LeukemiaLeucemia Bifenotipica ou Bilinear AgudaSindrome MielodisplasicaUS 1 site in the US

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

M.D. Anderson Cancer Center

📍 Houston👥 50 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DMultiple MyelomaSmoldering Multiple MyelomaAmyloidosisUS 1 site in the US

Registry for Adults With Plasma Cell Disorders (PCD's)

UNC Lineberger Comprehensive Cancer Center

📍 Chapel Hill👥 2000 participants📅 Completion: 2029-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Acute Myeloid LeukemiaUS 2 sites in the US

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

City of Hope Medical Center

📍 Duarte, Tampa👥 35 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Linfocitica CronicaLinfoma Linfocitico de Pequenas CelulasUS 8 sites in the US

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Memorial Sloan Kettering Cancer Center

📍 Basking Ridge, Boston, Commack, Evanston, Harrison, Middletown, New York, Uniondale👥 230 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DFpdmmDoencas Hematologicas HereditariasUS 1 site in the US

Longitudinal Studies of Patient With FPDMM

National Human Genome Research Institute (NHGRI)

📍 Bethesda👥 1000 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide Aguda Recidivada ou RefratariaLeucemia Mieloide Aguda Secundaria Recidivada ou RefratariaLeucemia Mieloide Aguda Originada de Sindrome MielodisplasicaUS 1 site in the US

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Jennifer Saultz

📍 Portland👥 51 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DLeucemia Mieloide AgudaUS 1 site in the US

Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

University of Southern California

📍 Los Angeles👥 250 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide Aguda RefratariaUS 2 sites in the US

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Ohio State University Comprehensive Cancer Center

📍 Columbus, Sacramento👥 28 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Mieloide AgudaUS 1 site in the US

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

University of Maryland, Baltimore

📍 Baltimore👥 39 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaLinfoma Nao HodgkinMieloma MultiploUS 6 sites in the US

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

CellCentric Ltd.

📍 Atlanta, Bethesda, Indianapolis, Omaha, Philadelphia👥 250 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Asma Leve Moderada Com Sensibilizacao AlergicaUS 1 site in the US

5HTP Regulation Of Asthma In Children

Indiana University

📍 Indianapolis👥 20 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Linfocitica CronicaLinfoma Linfocitico de Pequenas CelulasUS 1 site in the US

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

📍 Houston👥 168 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Chronic Lymphocytic Leukemia Small Lymphocytic LymphomaUS 7 sites in the US

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Ascentage Pharma Group Inc.

📍 Boston, Canton, Charlotte, Cleveland, Duarte, Jacksonville, Seattle👥 144 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Acute Myeloid LeukemiaSindrome MielodisplasicaUS 3 sites in the US

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Edgewood Oncology Inc.

📍 Duarte, Houston, New York👥 80 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Myelodysplastic SyndromeLeucemia Mielomonochitica CronicaSindrome Mielodisplasica Neoplasia MieloproliferativaUS 22 sites in the US

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

📍 Atlanta, Boston, Buffalo, Charleston, Columbus, Dallas, Durham, Hackensack👥 316 participants📅 Completion: 2028-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DLinfoma Difuso de Grandes Celulas bLinfoma b de Alto GrauLinfoma b Nao EspecificadoUS 1 site in the US

Study of CAR-T Therapy in Older Patients

Memorial Sloan Kettering Cancer Center

📍 New York👥 154 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaLeucemia Aguda de Linhagem AmbiguaSindrome MielodisplasicaUS 1 site in the US

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Fred Hutchinson Cancer Center

📍 Seattle👥 120 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Linfoma Difuso de Grandes Celulas b Recidivado RefratarioUS 6 sites in the US

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

📍 Baltimore, Cerritos, Louisville, Stony Brook, Tucson, Tyler👥 501 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mantle Cell LymphomaUS 1 site in the US

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

📍 Duarte👥 36 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Plasma Cell MyelomaUS 516 sites in the US

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

ECOG-ACRIN Cancer Research Group

📍 Aberdeen, Adrian, Albuquerque, Allentown, Alton, Ames, Anaconda, Anchorage👥 1450 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Linfoma Folicular Recidivado ou RefratarioUS 1 site in the US

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Joseph Tuscano

📍 Sacramento👥 23 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Diffuse Large b Cell LymphomaHigh Grade b Cell LymphomaFollicular LymphomaUS 9 sites in the US

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

AstraZeneca

📍 Austin, Charlotte, Columbus, Houston, Louisville, Milwaukee, New Brunswick, Pittsburgh👥 317 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Primary Cns Diffuse Large b Cell LymphomaUS 43 sites in the US

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

National Cancer Institute (NCI)

📍 Ankeny, Carroll, Chapel Hill, Charleston, City of Saint Peters, Clive, Columbus, Coral Gables👥 47 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Follicular LymphomaMarginal Zone LymphomaUS 4 sites in the US

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Enterome

📍 Boston, Rochester, Seattle👥 80 participants📅 Completion: 2034-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide Aguda Refrataria ou RecidivadaUS 1 site in the US

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Keystone Nano, Inc

📍 Charlottesville👥 15 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Diffuse Large b Cell LymphomaBurkitt LymphomaLinfoma b Agressivo Alto GrauUS 1 site in the US

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

National Cancer Institute (NCI)

📍 Bethesda👥 55 participants📅 Completion: 2031-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaLeucemia Linfoide AgudaUS 24 sites in the US

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Janssen Research & Development, LLC

📍 Albuquerque, Boston, Buffalo, Chicago, Dallas, Detroit, Duarte, Grand Rapids👥 420 participants📅 Completion: 2030-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Mantle Cell LymphomaUS 3 sites in the US

Avo In R/R And Previously Untreated MCL

Austin I Kim

📍 Boston, Chicago👥 72 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Large b Cell LymphomaDlbclUS 2 sites in the US

CAR-T Followed by Bispecific Antibodies

Abramson Cancer Center at Penn Medicine

📍 Omaha, Philadelphia👥 42 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1b Cell Non Hodgkin LymphomaLinfoma de Richter Transformacao de CllLeucemia Linfocitica CronicaUS 1 site in the US

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Mayo Clinic

📍 Rochester👥 25 participants📅 Completion: 2040-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Chronic Lymphocytic LeukemiaUS 11 sites in the US

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

AbbVie

📍 Atlanta, Boston, Chapel Hill, Charlotte, Columbus, Duluth, Hackensack, Hattiesburg👥 75 participants📅 Completion: 2029-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Linfoma Difuso de Grandes Celulas bUS 10 sites in the US

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ImmunoVaccine Technologies, Inc. (IMV Inc.)

📍 Atlanta, Fountain Valley, Greenville, Indianapolis, New Orleans, Omaha, Pittsburgh, Santa Fe👥 102 participants📅 Completion: 2025-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 1 site in the US

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Fred Hutchinson Cancer Center

📍 Seattle👥 20 participants📅 Completion: 2031-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Mieloma Multiplo Recidivado RefratarioUS 14 sites in the US

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

BeOne Medicines

📍 Atlanta, Birmingham, Columbus, Duarte, Hackensack, Irvine, Madison, Miami👥 246 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DAcute Myeloid LeukemiaMyelodysplastic SyndromesUS 1 site in the US

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

Washington University School of Medicine

📍 St Louis👥 325 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Follicular LymphomaUS 3 sites in the US

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Juan P. Alderuccio, MD

📍 Ann Arbor, Miami, New Brunswick👥 100 participants📅 Completion: 2030-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaSindrome MielodisplasicaUS 1 site in the US

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

📍 Houston👥 42 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1b Cell Acute Lymphoblastic LeukemiaUS 1 site in the US

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Baylor College of Medicine

📍 Houston👥 38 participants📅 Completion: 2040-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DLinfoma Primario do Sistema Nervoso CentralLinfoma Secundario do Sistema Nervoso CentralLeucemiaUS 1 site in the US

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

M.D. Anderson Cancer Center

📍 Houston👥 100 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Multiple MyelomaUS 18 sites in the US

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Pfizer

📍 Aventura, Basking Ridge, Commack, Coral Gables, Coral Springs, Deerfield Beach, Harrison, Hollywood👥 944 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Meningioma Grau ii IiiUS 3 sites in the US

NEO100 and High-Grade Meningioma

Neonc Technologies, Inc.

📍 Dallas, Los Angeles, Santa Monica👥 30 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Diffuse Large b Cell LymphomaUS 1 site in the US

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Mehrdad Abedi, MD

📍 Sacramento👥 36 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2b Cell Acute Lymphoblastic LeukemiaUS 12 sites in the US

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Etan Orgel

📍 Ann Arbor, Charlotte, Chicago, Dallas, Denver, Houston, Los Angeles, Minneapolis👥 240 participants📅 Completion: 2031-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Difuso Linfoma b Celulas GrandesLinfoma Celulas MantoLinfoma SncUS 1 site in the US

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

University of Colorado, Denver

📍 Aurora👥 68 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Diffuse Large b Cell LymphomaUS 20 sites in the US

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Merck Sharp & Dohme LLC

📍 Baltimore, Beverly Hills, Billings, Boca Raton, Boston, Clermont, Edgewood, Glendale👥 290 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Mieloide AgudaUS 44 sites in the US

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

PedAL BCU, LLC

📍 Ann Arbor, Atlanta, Aurora, Boston, Chicago, Columbia, Columbus, Dallas👥 98 participants📅 Completion: 2031-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaUS 2 sites in the US

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Hackensack Meridian Health

📍 Hackensack, Washington D.C.👥 66 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DMath Learning DisabilityDyscalculiaDevelopmental DisabilityUS 1 site in the US

Interventions in Mathematics and Cognitive Skills

Stanford University

📍 Palo Alto👥 180 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Plasma Cell MyelomaUS 1 site in the US

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Emory University

📍 Atlanta👥 34 participants📅 Completion: 2027-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Multiple MyelomaUS 24 sites in the US

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

European Myeloma Network B.V.

📍 Allentown, Baltimore, Boston, Chicago, Cincinnati, Cleveland, Columbus, Denver👥 1594 participants📅 Completion: 2032-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 12 sites in the US

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Loxo Oncology, Inc.

📍 Anaheim, Bethesda, Billings, Cerritos, Fort Myers, Kingwood, Nashville, Palo Alto👥 662 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DFollicular LymphomaLinfoma Difuso de Grandes Celulas bLinfoma de Celulas do MantoUS 1 site in the US

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Adaptive Biotechnologies

📍 Palo Alto👥 300 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide Aguda Relapso RefratariaUS 1 site in the US

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Medical College of Wisconsin

📍 Milwaukee👥 40 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaUS 1 site in the US

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

📍 Columbus👥 52 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Linfoma Difuso de Grandes Celulas bLinfoma de Celulas do MantoLinfoma FolicularUS 6 sites in the US

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

PeproMene Bio, Inc.

📍 Charlotte, Duarte, Kansas City, Minneapolis, Seattle, Stanford👥 36 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Richter SyndromeLeucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 1 site in the US

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic

📍 Rochester👥 27 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mieloma MultiploLeucemia de PlasmocitosUS 1 site in the US

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

University of Utah

📍 Salt Lake City👥 120 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Diffuse Large b Cell LymphomaHigh Grade b Cell LymphomaTransformed LymphomaUS 1 site in the US

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Washington University School of Medicine

📍 St Louis👥 15 participants📅 Completion: 2028-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Linfoma Difuso de Grandes Celulas bLinfoma Folicular de Grandes Celulas bTransformacao de Linfoma IndolenteUS 14 sites in the US

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Janssen Research & Development, LLC

📍 Austin, Charlotte, Cleveland, Denver, Duarte, Houston, Iowa City, Lexington👥 439 participants📅 Completion: 2029-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Mieloide AgudaUS 20 sites in the US

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Priothera SAS

📍 Atlanta, Aurora, Baltimore, Birmingham, Boston, Cincinnati, Cleveland, Dallas👥 366 participants📅 Completion: 2029-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Mieloma Multiplo Recidivado ou RefratarioUS 38 sites in the US

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Celgene

📍 Abilene, Albuquerque, Allentown, Ann Arbor, Athens, Baltimore, Baton Rouge, Boston👥 810 participants📅 Completion: 2033-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mantle Cell LymphomaUS 1 site in the US

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

M.D. Anderson Cancer Center

📍 Houston👥 30 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaSindrome MielodisplasicaUS 3 sites in the US

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

medac GmbH

📍 Chicago, Columbus, Richmond👥 36 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Linfocitica CronicaTransformacao de RichterUS 1 site in the US

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M.D. Anderson Cancer Center

📍 Houston👥 60 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Mieloma MultiploUS 1 site in the US

LMY-920 for Treatment of Relapsed or Refractory Myeloma

Luminary Therapeutics

📍 Cleveland👥 30 participants📅 Completion: 2025-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Multiple MyelomaUS 60 sites in the US

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Janssen Research & Development, LLC

📍 Ann Arbor, Baltimore, Bethesda, Charlotte, Chicago, Cincinnati, Cleveland, Clovis👥 1590 participants📅 Completion: 2033-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Mieloide AgudaUS 163 sites in the US

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

📍 Albany, Albuquerque, Allentown, Anaconda, Ashland, Basking Ridge, Baton Rouge, Bellevue👥 153 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DMultiple Myelomaal AmiloidoseLeucemia de Celulas PlasmaticasUS 1 site in the US

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

University of Alabama at Birmingham

📍 Birmingham👥 5000 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Linfocitica CronicaLinfoma Linfocitico de Pequenas CelulasMacroglobulinemia de WaldenstromUS 13 sites in the US

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Carna Biosciences, Inc.

📍 Baltimore, Chicago, Durham, Fort Wayne, Houston, Maumee, Miami Beach, Milwaukee👥 120 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaUS 22 sites in the US

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

AbbVie

📍 Aurora, Austin, Chapel Hill, Cincinnati, Eugene, Fairfax, Fort Wayne, Hinsdale👥 210 participants📅 Completion: 2029-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Acute Myeloid LeukemiaLeucemia Mieloide Aguda RecidivadaLeucemia Mieloide Aguda RefratariaUS 1 site in the US

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

📍 Duarte👥 27 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Linfoma Nao Hodgkin Agressivo Celulas bLinfoma Nao Hodgkin Indolente Celulas bLinfoma de Celulas do MantoUS 1 site in the US

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Medical University of South Carolina

📍 Charleston👥 27 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaUS 4 sites in the US

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

GlaxoSmithKline

📍 Chapel Hill, Chattanooga, Grand Rapids, Nashville👥 153 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DLeucemia Linfocitica CronicaMacroglobulinemia de WaldenstromLinfoma de Celulas do MantoUS 1 site in the US

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

National Heart, Lung, and Blood Institute (NHLBI)

📍 Bethesda👥 135 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DMultiple MyelomaUS 2 sites in the US

The Ambient Light Multiple Myeloma Study

Icahn School of Medicine at Mount Sinai

📍 New York👥 200 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Glioblastoma Idh WildtypeAstrocitoma Idh Mutante Grau 3US 8 sites in the US

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Debiopharm International SA

📍 Chicago, Dallas, Houston, New York, Salt Lake City, San Antonio, Seattle👥 116 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Follicular LymphomaLow Grade Non Hodgkin LymphomaUS 5 sites in the US

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Reid Merryman, MD

📍 Boston, Columbus, Milwaukee, Rochester👥 100 participants📅 Completion: 2030-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Large b Cell LymphomaLinfoma Nao Hodgkin Recidivado RefratarioUS 30 sites in the US

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma, Inc.

📍 Albuquerque, Allentown, Augusta, Buffalo, Cincinnati, Cleveland, Dallas, Denver👥 270 participants📅 Completion: 2031-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Multiple MyelomaUS 42 sites in the US

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Bristol-Myers Squibb

📍 Ann Arbor, Athens, Atlanta, Augusta, Aurora, Charlotte, Chicago, Cincinnati👥 1216 participants📅 Completion: 2036-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Linfoma Difuso de Grandes Celulas b Recidivado RefratarioUS 4 sites in the US

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Dipenkumar Modi

📍 Charlottesville, Dallas, Detroit, Indianapolis👥 32 participants📅 Completion: 2028-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Mantle Cell LymphomaBlastoid Variant Mantle Cell LymphomaPleomorphic Variant Mantle Cell LymphomaUS 2 sites in the US

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center

📍 Duarte, Salt Lake City👥 50 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Sindrome de Richter Dlbcl em Cll SllLinfoma Nao Hodgkin b Transformado Recidivado RefratarioUS 3 sites in the US

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Aseel Alsouqi

📍 Columbus, New York, Salt Lake City👥 24 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DLeucemia Linfocitica CronicaLinfoma Nao Hodgkin IndolenteUS 2 sites in the US

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

Mayo Clinic

📍 Rochester, Scottsdale👥 70 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide Aguda Com Mutacao Npm1Leucemia Mieloide Aguda Com Rearranjo Kmt2aUS 21 sites in the US

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

National Cancer Institute (NCI)

📍 Aventura, Baltimore, Chapel Hill, Charlotte, Charlottesville, Chicago, Cincinnati, Columbus👥 28 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Large b Cell LymphomaDiffuse Large b Cell LymphomaMantle Cell LymphomaUS 1 site in the US

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Joshua Sasine, MD, PhD

📍 Los Angeles👥 20 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DLeucemia Mieloide AgudaUS 1 site in the US

Assessment of Geriatric Evaluations Impact on New AML Guidance

Abramson Cancer Center at Penn Medicine

📍 Philadelphia👥 100 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mantle Cell LymphomaUS 1 site in the US

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Academic and Community Cancer Research United

📍 Rochester👥 100 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Xerostomia Induzida Por RadioterapiaUS 18 sites in the US

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

MeiraGTx, LLC

📍 Baltimore, Boston, Buffalo, Chapel Hill, Charlotte, Columbia, Dallas, Detroit👥 276 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mieloma MultiploUS 5 sites in the US

Limited-duration Teclistamab

Abramson Cancer Center at Penn Medicine

📍 Iowa City, Little Rock, New York, Philadelphia👥 75 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Diffuse Large b Cell LymphomaFollicular LymphomaMantle Cell LymphomaUS 1 site in the US

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Weill Medical College of Cornell University

📍 New York👥 15 participants📅 Completion: 2031-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaUS 1 site in the US

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

OHSU Knight Cancer Institute

📍 Portland👥 27 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 5 sites in the US

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Merck Sharp & Dohme LLC

📍 Long Beach, Pembroke Pines, Portland, Spokane, Springdale👥 735 participants📅 Completion: 2035-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Diffuse Large b Cell LymphomaUS 10 sites in the US

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

AstraZeneca

📍 Baltimore, Detroit, Jacksonville, La Jolla, Lubbock, Olympia, Orange, Rockville👥 80 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 28 sites in the US

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Janssen Research & Development, LLC

📍 Boise, Cerritos, Cincinnati, Eugene, Flemington, Fort Worth, Grand Junction, Hinsdale👥 320 participants📅 Completion: 2029-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaSindrome MielodisplasicaUS 2 sites in the US

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Montefiore Medical Center

📍 Houston, The Bronx👥 38 participants📅 Completion: 2030-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Diffuse Large b Cell LymphomaHigh Grade b Cell LymphomaTransformed Indolent b Cell Non Hodgkin LymphomaUS 6 sites in the US

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

📍 Charlottesville, Chicago, Duarte, Oklahoma City, Sacramento, Winston-Salem👥 30 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Mantle Cell LymphomaUS 1 site in the US

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

Alvaro Alencar, MD

📍 Miami👥 27 participants📅 Completion: 2032-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaUS 1 site in the US

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Mayo Clinic

📍 Rochester👥 100 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mantle Cell LymphomaUS 1 site in the US

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

📍 Duarte👥 40 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DSmoldering Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceUS 7 sites in the US

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

Memorial Sloan Kettering Cancer Center

📍 Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, Uniondale👥 200 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mieloma Multiplo Com Nefropatia Por CilindrosGamopatia Monoclonal de Significancia RenalUS 8 sites in the US

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Memorial Sloan Kettering Cancer Center

📍 Basking Ridge, Chapel Hill, Commack, Harrison, Middletown, Montvale, New York, Uniondale👥 20 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Mantle Cell LymphomaUS 13 sites in the US

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Hoffmann-La Roche

📍 Ann Arbor, Charlottesville, Chesterfield, Coral Gables, Duarte, El Paso, Morgantown, New Brunswick👥 182 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Follicular LymphomaUS 14 sites in the US

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Regeneron Pharmaceuticals

📍 Boston, Chapel Hill, Charlotte, Charlottesville, Cleveland, Detroit, Houston, Los Angeles👥 822 participants📅 Completion: 2029-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaUS 9 sites in the US

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

AstraZeneca

📍 Ann Arbor, Atlanta, Boston, Duarte, Fairfax, Irvine, New York, Philadelphia👥 226 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DHematologic MalignancyLeucemia Linfocitica AgudaLeucemia Mieloide AgudaUS 4 sites in the US

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Children's Hospital Medical Center, Cincinnati

📍 Aurora, Cincinnati, Houston, Milwaukee👥 30 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 39 sites in the US

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Merck Sharp & Dohme LLC

📍 Austin, Berkeley, Billings, Broomall, Buffalo, Charlotte, Charlottesville, Chattanooga👥 1200 participants📅 Completion: 2032-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaInsuficiencia RenalUS 1 site in the US

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Augusta University

📍 Augusta👥 30 participants📅 Completion: 2027-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Follicular LymphomaMarginal Zone LymphomaUS 7 sites in the US

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Regeneron Pharmaceuticals

📍 Hattiesburg, Indianapolis, Lebanon, Los Angeles, Plantation, Stony Brook, Waukesha👥 470 participants📅 Completion: 2029-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DMultiple MyelomaUS 1 site in the US

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

All4Cure

📍 Seattle👥 450 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DLeucemia Linfocitica CronicaLinfoma de Celulas do MantoMacroglobulinemia de WaldenstromUS 1 site in the US

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Mayo Clinic

📍 Rochester👥 100 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Multiple MyelomaUS 83 sites in the US

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

📍 Belton, Beverly Hills, Boston, Chicago, Cincinnati, Cleveland, Clovis, Dallas👥 492 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mieloma Multiplo Relapso RefratarioUS 12 sites in the US

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

Multiple Myeloma Research Consortium

📍 Atlanta, Boston, Charlotte, Chicago, Detroit, Duarte, Hackensack, Nashville👥 300 participants📅 Completion: 2030-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Hodgkin LymphomaLinfoma Difuso de Grandes Celulas b Cd30 PositivoLinfoma Anaplasico de Grandes Celulas Alk PositivoUS 1 site in the US

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Baylor College of Medicine

📍 Houston👥 90 participants📅 Completion: 2043-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Follicular LymphomaUS 57 sites in the US

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Genmab

📍 Albany, Albuquerque, Austin, Baltimore, Bethesda, Billings, Boulder, Charleston👥 1095 participants📅 Completion: 2037-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Multiple MyelomaUS 43 sites in the US

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Janssen Research & Development, LLC

📍 Ann Arbor, Atlanta, Baltimore, Baton Rouge, Buffalo, Canton, Charleston, Charlottesville👥 795 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Diffuse Large b Cell Lymphoma Recurrent RefractoryHigh Grade b Cell Lymphoma RecurrentPrimary Mediastinal Large b Cell Lymphoma RecurrentUS 1 site in the US

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Nathan Denlinger

📍 Columbus👥 18 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide Aguda Flt3 Mutada Npm1Leucemia Mieloide Aguda Flt3 Mutada Rearranjo Kmt2aUS 3 sites in the US

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Uma Borate

📍 Chapel Hill, Columbus, Philadelphia👥 30 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mantle Cell LymphomaUS 1 site in the US

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

M.D. Anderson Cancer Center

📍 Houston👥 50 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaLeucemia Linfoblastica AgudaSindrome MielodisplasicaUS 1 site in the US

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

📍 Duarte👥 15 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DHematologic MalignanciesLymphomaMultiple MyelomaUS 1 site in the US

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

UNC Lineberger Comprehensive Cancer Center

📍 Chapel Hill👥 500 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mantle Cell LymphomaMarginal Zone LymphomaUS 1 site in the US

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

University of Utah

📍 Salt Lake City👥 27 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 4 sites in the US

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Inhye Ahn

📍 Boston, Scarborough👥 60 participants📅 Completion: 2032-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DColangiocarcinomaMieloma MultiploCancer de ColonUS 1 site in the US

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Washington University School of Medicine

📍 St Louis👥 990 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Marginal Zone LymphomaFollicular LymphomaUS 1 site in the US

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

H. Lee Moffitt Cancer Center and Research Institute

📍 Tampa👥 43 participants📅 Completion: 2029-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaUS 4 sites in the US

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Delta-Fly Pharma, Inc.

📍 Burlington, Charlottesville, Orange, Winston-Salem👥 39 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1b Cell Acute Lymphoblastic LeukemiaDiffuse Large b Cell LymphomaBurkitt LymphomaUS 17 sites in the US

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Merck Sharp & Dohme LLC

📍 Aurora, Boston, Fargo, Grand Rapids, Houston, Iowa City, Kansas City, Los Angeles👥 90 participants📅 Completion: 2029-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Sindrome MielodisplasicaLeucemia Mieloide AgudaUS 1 site in the US

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Vanderbilt-Ingram Cancer Center

📍 Nashville👥 60 participants📅 Completion: 2027-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Chronic Lymphocytic LeukemiaUS 31 sites in the US

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

AbbVie

📍 Aurora, Austin, Bethesda, Charlotte, Cleveland, Clovis, Dallas, Des Moines👥 170 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaLeucemia Mieloide MonoциticaUS 1 site in the US

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

University of Colorado, Denver

📍 Aurora👥 30 participants📅 Completion: 2027-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Linfoma Folicular Grau 1Linfoma Folicular Grau 2Linfoma Folicular Grau 3aUS 1 site in the US

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

City of Hope Medical Center

📍 Duarte👥 41 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Acute Myeloid LeukemiaUS 24 sites in the US

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Stemline Therapeutics, Inc.

📍 Boston, Buffalo, Charlotte, Chicago, Cleveland, Dallas, Detroit, Hackensack👥 83 participants📅 Completion: 2030-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Diffuse Large b Cell LymphomaHigh Grade b Cell LymphomaTransformed Indolent Non Hodgkin LymphomaUS 1 site in the US

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Abramson Cancer Center at Penn Medicine

📍 Philadelphia👥 31 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DHigh Risk Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid LeukemiaPrimary Refractory Acute Myeloid LeukemiaUS 1 site in the US

Novel Digital Application for Patients With Acute Leukemia

Massachusetts General Hospital

📍 Boston👥 200 participants📅 Completion: 2030-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Multiple MyelomaUS 9 sites in the US

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Janssen Research & Development, LLC

📍 Cleveland, Denver, Durham, New Haven, New York, Richmond, Rochester, San Francisco👥 210 participants📅 Completion: 2029-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Follicular LymphomaUS 3 sites in the US

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Beth Israel Deaconess Medical Center

📍 Boston, New York, Stanford👥 35 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 4 sites in the US

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

VA Office of Research and Development

📍 Durham, Kansas City, San Francisco, Seattle👥 100 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Follicular LymphomaLarge b Cell LymphomaUS 12 sites in the US

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

AstraZeneca

📍 Charlotte, Columbus, Duarte, Houston, Milwaukee, New York, Philadelphia, Pittsburgh👥 240 participants📅 Completion: 2029-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaSindrome Mielodisplasica Alto RiscoUS 10 sites in the US

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Stelexis BioSciences

📍 Aurora, Boston, Cleveland, Columbus, Duarte, Houston, New York, St Louis👥 125 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DChronic Lymphocytic LeukemiaMonoclonal b Cell LymphocytosisHealthy ControlUS 1 site in the US

Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects

Mayo Clinic

📍 Rochester👥 50 participants📅 Completion: 2028-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1b Cell LymphomaLinfoma do MantoLinfoma FolicularUS 5 sites in the US

SynKIR-310 for Relapsed/Refractory B-NHL

Verismo Therapeutics

📍 Atlanta, Denver, Fairway, New Brunswick, Philadelphia👥 36 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Follicular LymphomaMarginal Zone LymphomaUS 3 sites in the US

Epco, Zanu, Ritux for R/R FL or MZL

Reid Merryman, MD

📍 Boston, Columbus, New York👥 45 participants📅 Completion: 2030-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mantle Cell LymphomaUS 1 site in the US

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

City of Hope Medical Center

📍 Duarte👥 27 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Mieloide AgudaUS 42 sites in the US

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Daiichi Sankyo

📍 Ann Arbor, Atlanta, Baltimore, Boston, Buffalo, Chapel Hill, Chicago, Cleveland👥 700 participants📅 Completion: 2030-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Mieloma Multiplo Recidivado ou RefratarioUS 13 sites in the US

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

📍 Atlanta, Birmingham, Boston, Charlotte, Cleveland, Jacksonville, Los Angeles, Miami👥 440 participants📅 Completion: 2032-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Linfoma de Celulas do MantoUS 1 site in the US

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

📍 Duarte👥 10 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Multiple MyelomaUS 24 sites in the US

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GlaxoSmithKline

📍 Ann Arbor, Atlanta, Aurora, Austin, Beverly Hills, Billings, Charlotte, Columbus👥 520 participants📅 Completion: 2031-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Multiple MyelomaUS 7 sites in the US

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Memorial Sloan Kettering Cancer Center

📍 Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, Uniondale👥 215 participants📅 Completion: 2027-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DDiffuse Large b Cell LymphomaHigh Grade b Cell LymphomaUS 1 site in the US

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Hua-Jay J Cherng, MD

📍 New York👥 40 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DLeucemia Mieloide AgudaNeoplasia Mieloide Alto GrauLeucemia Linfoblastica Aguda bUS 1 site in the US

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

University of Washington

📍 Seattle👥 50 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Diffuse Large b Cell LymphomaUS 36 sites in the US

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Merck Sharp & Dohme LLC

📍 Albany, Alexandria, Billings, Bridgeton, Charlottesville, Clermont, Fort Wayne, Fullerton👥 1046 participants📅 Completion: 2032-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Richter TransformationLinfoma Difuso de Grandes Celulas b TransformadoUS 1 site in the US

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

City of Hope Medical Center

📍 Duarte👥 23 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Chronic Lymphocytic Leukemia Small Lymphocytic LymphomaUS 1 site in the US

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Seema Bhat

📍 Columbus👥 61 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DMantle Cell LymphomaUS 1 site in the US

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

📍 Milwaukee👥 300 participants📅 Completion: 2044-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Dlbcl Ebv Positivo Recidivado RefratarioUS 1 site in the US

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Thomas Jefferson University

📍 Philadelphia👥 30 participants📅 Completion: 2028-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Follicular LymphomaMarginal Zone LymphomaUS 1 site in the US

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Masonic Cancer Center, University of Minnesota

📍 Minneapolis👥 65 participants📅 Completion: 2031-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Mieloide AgudaLeucemia Mieloide CronicaSindrome MielodisplasicaUS 1 site in the US

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

University of Illinois at Chicago

📍 Chicago👥 38 participants📅 Completion: 2032-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Linfoma Difuso de Grandes Celulas bUS 31 sites in the US

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

📍 Albany, Anchorage, Aurora, Baton Rouge, Boise, Boston, Chattanooga, Clovis👥 100 participants📅 Completion: 2029-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaLeucemia Linfoide Aguda RecidivadaUS 1 site in the US

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

St. Jude Children's Research Hospital

📍 Memphis👥 29 participants📅 Completion: 2031-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Mieloide AgudaLeucemia Linfoide AgudaSindrome MielodisplasicaUS 1 site in the US

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

📍 Duarte👥 35 participants📅 Completion: 2028-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DMild Cognitive ImpairmentDemencia LeveUS 1 site in the US

The "Let's Talk Tech" Tool to Support Decision Making About Technology Use

University of Washington

📍 Seattle👥 240 participants📅 Completion: 2026-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Mieloide AgudaUS 1 site in the US

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Daiichi Sankyo

📍 Westbury👥 130 participants📅 Completion: 2032-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mieloma Multiplo Recidivado RefratarioUS 2 sites in the US

ELISA in Relapsed/Refractory MM

Massachusetts General Hospital

📍 Boston👥 30 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMantle Cell LymphomaUS 1 site in the US

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutchinson Cancer Center

📍 Seattle👥 20 participants📅 Completion: 2032-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 20 sites in the US

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

BeOne Medicines

📍 Atlanta, Aurora, Baton Rouge, Bethesda, Cleveland, Dayton, Eugene, Fort Myers👥 250 participants📅 Completion: 2030-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Mieloide AgudaUS 41 sites in the US

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Janssen Research & Development, LLC

📍 Baton Rouge, Boston, Buffalo, Canton, Charlotte, Chicago, Cleveland, Dallas👥 600 participants📅 Completion: 2029-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mantle Cell LymphomaUS 4 sites in the US

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

Christine Ryan

📍 Boston, New York, St Louis👥 60 participants📅 Completion: 2039-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DDementia MildDementia ModerateDor CronicaUS 1 site in the US

Pain With Dementia

Duke University

📍 Durham👥 60 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DLinfoma IndolenteLinfoma FolicularLinfoma de Zona MarginalUS 1 site in the US

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

UNC Lineberger Comprehensive Cancer Center

📍 Chapel Hill👥 40 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Richter Transformation DlbclLeucemia Linfocitica CronicaUS 1 site in the US

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Roswell Park Cancer Institute

📍 Buffalo👥 32 participants📅 Completion: 2030-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Leucemia Linfocitica CronicaLinfoma Nao HodgkinUS 16 sites in the US

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Eli Lilly and Company

📍 Atlanta, Boston, Chicago, Columbus, Durham, Houston, Lake Success, Miami👥 279 participants📅 Completion: 2032-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Linfoma Difuso de Grandes Celulas bUS 65 sites in the US

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Merck Sharp & Dohme LLC

📍 Amarillo, Aurora, Austin, Baton Rouge, Boca Raton, Bozeman, Buffalo, Burbank👥 594 participants📅 Completion: 2032-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Diffuse Large b Cell LymphomaHigh Grade b Cell LymphomaTransformed Follicular LymphomaUS 1 site in the US

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Joseph Tuscano

📍 Sacramento👥 25 participants📅 Completion: 2030-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DColangiocarcinomaMieloma MultiploCancer ColorretalUS 1 site in the US

Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid

Washington University School of Medicine

📍 St Louis👥 240 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Follicular LymphomaUS 12 sites in the US

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Celgene

📍 Anchorage, Austin, Duarte, Fredericksburg, Hattiesburg, Marietta, Mobile, Newnan👥 400 participants📅 Completion: 2030-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaUS 33 sites in the US

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

BeOne Medicines

📍 Aurora, Baltimore, Baton Rouge, Boston, Chapel Hill, Charlotte, Chattanooga, Chicago👥 630 participants📅 Completion: 2031-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Mieloma MultiploUS 1 site in the US

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

H. Lee Moffitt Cancer Center and Research Institute

📍 Tampa👥 39 participants📅 Completion: 2029-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mielomonochitica CronicaLeucemia Meloide Aguda MonociticaUS 6 sites in the US

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Solu Therapeutics, Inc

📍 Boston, Houston, Portland, Rochester, Stanford, Tampa👥 105 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 34 sites in the US

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BeOne Medicines

📍 Baton Rouge, Boston, Chapel Hill, Charlotte, Chicago, Dayton, Detroit, Durham👥 500 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Linfocitica CronicaLinfoma Linfocitico de Pequenas CelulasUS 1 site in the US

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Zulfa Omer

📍 Cincinnati👥 34 participants📅 Completion: 2034-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Multiple MyelomaSecondary ImmunodeficiencyUS 7 sites in the US

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Takeda

📍 Albany, Baltimore, Detroit, Mobile, Orange, St Louis, Westwood👥 183 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Acute Myeloid LeukemiaSindrome Mielodisplasica Alto RiscoLeucemia Mielomonocitica CronicaUS 11 sites in the US

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Crossbow Therapeutics, Inc.

📍 Boston, Chicago, Duarte, Houston, Nashville, New York, Palo Alto, Philadelphia👥 72 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Linfoma de Celulas do MantoUS 5 sites in the US

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

National Cancer Institute (NCI)

📍 Atlanta, Duarte, Nashville👥 20 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Leucemia Mieloide AgudaUS 34 sites in the US

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Kura Oncology, Inc.

📍 Albuquerque, Aurora, Austin, Chapel Hill, Charlottesville, Clovis, Columbus, Dallas👥 1300 participants📅 Completion: 2031-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaUS 1 site in the US

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

Zulfa Omer

📍 Cincinnati👥 62 participants📅 Completion: 2032-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 2 sites in the US

Mosunetuzumab for CLL MRD Clearance

Inhye Ahn

📍 Boston👥 40 participants📅 Completion: 2032-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Mieloma Multiplo Recidivado RefratarioUS 1 site in the US

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Medical College of Wisconsin

📍 Milwaukee👥 31 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Multiple MyelomaUS 4 sites in the US

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

CellCentric Ltd.

📍 Atlanta, Bethesda, Omaha, Philadelphia👥 100 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Multiple MyelomaUS 1 site in the US

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University

📍 Atlanta👥 94 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaSindrome MielodisplasicaUS 2 sites in the US

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Remedy Plan, Inc.

📍 Houston, New York👥 24 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Leucemia Linfocitica CronicaLinfoma Linfocitico PequenoUS 1 site in the US

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Zulfa Omer

📍 Cincinnati👥 22 participants📅 Completion: 2029-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Linfoma Difuso de Grandes Celulas bLinfoma de Celulas do MantoLinfoma FolicularUS 5 sites in the US

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

LTZ Therapeutics, Inc.

📍 Buffalo, Duarte, Nashville, Seattle, St Louis👥 42 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Multiple MyelomaUS 3 sites in the US

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Janssen Research & Development, LLC

📍 Cleveland, New York, Tampa👥 60 participants📅 Completion: 2029-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaUS 1 site in the US

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

Fred Hutchinson Cancer Center

📍 Seattle👥 30 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Multiple MyelomaHodgkin LymphomaNon Hodgkin LymphomaUS 1 site in the US

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

Thomas Jefferson University

📍 Philadelphia👥 100 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DMultiple MyelomaUS 7 sites in the US

A Dietary Study for People With Multiple Myeloma

Memorial Sloan Kettering Cancer Center

📍 Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, Uniondale👥 220 participants📅 Completion: 2028-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Multiple MyelomaUS 15 sites in the US

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

📍 Atlanta, Brooklyn, Durham, Farmington, Fort Myers, Iowa City, Los Angeles, Louisville👥 400 participants📅 Completion: 2031-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Mieloide AgudaSindrome MielodisplasicaNeoplasia Mielodisplasica MieloproliferativaUS 1 site in the US

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

University of Virginia

📍 Charlottesville👥 23 participants📅 Completion: 2031-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Linfoma Difuso de Grandes Celulas bLinfoma b Nao HodgkinLeucemia Linfocitica CronicaUS 1 site in the US

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

AvenCell Therapeutics, Inc.

📍 Nashville👥 178 participants📅 Completion: 2029-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DLymphomaMielomaSindrome de Liberacao de CitocinasUS 1 site in the US

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

University of Utah

📍 Salt Lake City👥 40 participants📅 Completion: 2029-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Multiple MyelomaUS 2 sites in the US

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

AbbVie

📍 Grand Rapids, Newnan👥 127 participants📅 Completion: 2031-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Leucemia Linfocitica CronicaLinfoma Linfocitico de Pequenas CelulasUS 1 site in the US

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

National Heart, Lung, and Blood Institute (NHLBI)

📍 Bethesda👥 30 participants📅 Completion: 2030-03

View details →Refer patient →ClinicalTrials.gov ↗

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Hematologic oncology clinical trialsrecruiting in the United States and Brazil

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Tissue Collection for Studies of Lymph Cancer

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Clonal Evolution in Follicular Lymphoma

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

The Indiana Myeloma Registry

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Registry for Adults With Plasma Cell Disorders (PCD's)

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Longitudinal Studies of Patient With FPDMM

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

5HTP Regulation Of Asthma In Children

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study of CAR-T Therapy in Older Patients

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Avo In R/R And Previously Untreated MCL

CAR-T Followed by Bispecific Antibodies

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NEO100 and High-Grade Meningioma

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Interventions in Mathematics and Cognitive Skills

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Hematologic oncology clinical trials
recruiting in the United States and Brazil